Section 8.3: Diabetes Mellitus & Metabolic Syndrome

USMLE Step 3 Exam

Track your progress as you read

Finished sections get a check mark.

1 Foundations - Biostatistics & Study Design

1.1 Study Designs & Clinical Trials 1.2 Hypothesis Testing & Statistical Significance 1.3 Measures of Association & Diagnostic Accuracy

2 Foundations - Epidemiology & Literature Interpretation

Section 2.1: Epidemiology & Risk Measures Section 2.2: Interpretation of Medical Literature & Ads Section 2.3: Preventive Medicine & Screening Guidelines

3 Foundations - Ethics & Communication

3.1 Medical Ethics & Patient Autonomy 3.2 Professionalism & Communication Skills 3.3 Legal Medicine & Informed Consent

4 Foundations - Patient Safety & Systems

Section 4.1: Patient Safety & Error Reduction Section 4.2: Quality Improvement & Systems-Based Practice Section 4.3: Healthcare Delivery Systems & Transitions of Care

5 Cardiovascular Management

5.1 Ischemic Heart Disease & Myocardial Infarction 5.2 Heart Failure & Cardiomyopathies 5.3 Arrhythmias & Conduction System Disorders 5.4 Vascular Diseases & Hypertension Management

6 Respiratory Management

Section 6.1: Obstructive Lung Diseases Section 6.2: Restrictive & Interstitial Lung Diseases Section 6.3: Infectious Pulmonary Diseases Section 6.4: Pulmonary Vascular & Pleural Diseases

7 Gastrointestinal & Hepatic Management

Esophageal & Gastric Disorders Intestinal & Colorectal Disorders Hepatic, Biliary, & Pancreatic Diseases Nutritional & Malabsorptive Syndromes

8 Renal, Urinary, & Endocrine Management

Section 8.1: Acute Kidney Injury & Chronic Kidney Disease Section 8.2: Fluid, Electrolyte, & Acid-Base Disorders Section 8.3: Diabetes Mellitus & Metabolic Syndrome Section 8.4: Thyroid, Adrenal, & Pituitary Disorders

9 Neurology, Special Senses, & Behavioral Health

9.1 Cerebrovascular Disease & Stroke 9.2 Neurodegenerative & Demyelinating Disorders 9.3 Psychiatric Emergencies & Substance Use Disorders 9.4 Common Mood, Anxiety, & Psychotic Disorders

10 Obstetrics & Gynecology

10.1 Antepartum Care & Pregnancy Complications 10.2 Intrapartum Management & Postpartum Care 10.3 Gynecology & Breast Disorders

11 Pediatrics, Human Development, & Multisystem Care

11.1 Normal Development & Childhood Immunizations 11.2 Common Pediatric & Neonatal Illnesses 11.3 Multisystem & Rheumatologic Diseases

12 Skin, Musculoskeletal, & CCS Case Management

Section 12.1: Common Dermatologic Presentations Section 12.2: Acute & Chronic Musculoskeletal Injuries Section 12.3: Computer-Based Case Simulations (CCS) Strategy

Section 8.3: Diabetes Mellitus & Metabolic Syndrome

Key Takeaways Explain This Topic AI

DKA (2024 adult consensus) presents with glucose ≥ 200 mg/dL or known diabetes (about 10% are euglycemic), elevated ketones, and pH < 7.3 and/or bicarbonate < 18; HHS presents with glucose > 600 mg/dL, osmolarity > 320 mOsm/kg, and minimal ketosis.

Manage DKA/HHS with aggressive fluid resuscitation, insulin infusion, and potassium replacement; delay insulin if potassium is < 3.5 mEq/L (2024 adult consensus).

Transition from intravenous to subcutaneous insulin in DKA only after the ketoacidosis has resolved (ketone <0.6 mmol/L and pH ≥7.3 or bicarbonate ≥18 mEq/L), giving basal insulin 2 hours prior to stopping the infusion.

First-line type 2 diabetes management is metformin; add SGLT-2 inhibitors or GLP-1 receptor agonists early for cardiorenal protection in patients with heart failure, CKD, or ASCVD.

Screen annually for diabetic complications: microalbuminuria (treat with ACEi/ARB if positive), retinopathy, and neuropathy, and screen for metabolic syndrome using ATP III criteria.

Last updated: October 2026

Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State

Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are life-threatening acute complications of diabetes mellitus. DKA is characterized by a triad of hyperglycemia (glucose ≥ 200 mg/dL or a known history of diabetes; about 10% present with euglycemic DKA), metabolic acidosis (arterial pH < 7.30 and serum bicarbonate < 18 mEq/L), and ketonemia/ketonuria (marked by elevated beta-hydroxybutyrate and acetoacetate). DKA occurs primarily in type 1 diabetes due to absolute insulin deficiency, which promotes lipolysis, fatty acid transport to the liver, and subsequent ketogenesis. Conversely, HHS occurs predominantly in type 2 diabetes and is defined by severe hyperglycemia (glucose > 600 mg/dL), high serum osmolality (> 320 mOsm/kg), and minimal or absent ketosis (pH > 7.30, bicarbonate > 18 mEq/L). In HHS, residual insulin secretion is sufficient to suppress lipolysis and ketogenesis but insufficient to prevent profound hyperglycemia and osmotic diuresis, leading to severe dehydration.

The management protocol for both DKA and HHS requires a highly structured approach:

Intravenous Fluids: Fluid resuscitation is the initial priority. Administer isotonic saline or a balanced crystalloid at 500–1,000 mL/h for the first 2–4 hours in adults without renal or cardiac compromise (smaller 250 mL boluses in older adults, heart failure, or dialysis). Subsequent fluid selection is based on corrected sodium and volume status. If corrected sodium is normal or high, switch to 0.45% saline. When serum glucose falls below 250 mg/dL in DKA (or 300 mg/dL in HHS), add 5–10% dextrose to the IV fluid. This allows the continuation of the insulin infusion to resolve ketosis (in DKA) or hyperosmolality (in HHS) while preventing hypoglycemia and cerebral edema.

Potassium Management: Before initiating insulin, serum potassium must be evaluated. Insulin drives potassium intracellularly, which can cause fatal cardiac arrhythmias. Under the 2024 adult consensus, if potassium is < 3.5 mEq/L, hold insulin and administer potassium chloride (about 10 mEq/h) until the potassium is > 3.5 mEq/L. If potassium is 3.5–5.0 mEq/L, administer potassium (20–30 mEq per liter of IV fluid) concurrently with insulin to maintain potassium between 4.0–5.0 mEq/L. If potassium is > 5.0 mEq/L, insulin can be started and potassium replacement begins once it falls below 5.0; recheck potassium 2 hours after insulin starts, then every 4 hours.

Insulin Administration: Administer a continuous regular insulin infusion at 0.1 units/kg/h (or a 0.1 unit/kg bolus followed by 0.1 units/kg/h). In DKA, do not stop the insulin infusion based on glucose levels alone; the infusion must continue until the ketoacidosis resolves. DKA is resolved when plasma ketone (β-hydroxybutyrate) is <0.6 mmol/L and venous pH is ≥7.3 or bicarbonate is ≥18 mEq/L (ideally glucose <200 mg/dL); the anion gap and urine ketones are not used as resolution criteria.

Transition to Subcutaneous Insulin: When the patient is hemodynamically stable, tolerating oral intake, and DKA has resolved (or osmolality has normalized in HHS), transition to a subcutaneous insulin regimen. To prevent immediate relapse into ketosis, administer the first dose of subcutaneous basal insulin 2 hours before discontinuing the intravenous insulin infusion.

Step-wise Management of Type 2 Diabetes

Pharmacotherapy for type 2 diabetes has evolved from a glucose-centric model to a risk-stratified, cardiorenal-protective framework:

First-line Therapy: Metformin is the first-line agent due to high efficacy, weight-neutral profile, low hypoglycemia risk, and low cost. It decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Metformin is contraindicated if eGFR is < 30 mL/min/1.73m2 due to lactic acidosis risk. Renal function must be monitored annually.

Cardiorenal Protection: In patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD) with albuminuria, specific agents should be added independent of baseline HbA1c:

SGLT-2 Inhibitors (e.g., empagliflozin, dapagliflozin): Block renal glucose reabsorption in the proximal convoluted tubule. They are preferred in patients with heart failure (reduced or preserved ejection fraction) and CKD progression (slowing GFR decline and reducing proteinuria). Side effects include genitourinary candidiasis, urinary tract infections, euglycemic DKA, and volume depletion.

GLP-1 Receptor Agonists (e.g., semaglutide, liraglutide, dulaglutide): Mimic incretin hormones to enhance glucose-dependent insulin secretion and delay gastric emptying. They are preferred in patients with predominant ASCVD or a high need for weight loss. Side effects include gastrointestinal distress and a risk of pancreatitis; they are contraindicated in patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2.

Other Adjunctive Agents: Other agents include DPP-4 inhibitors (weight-neutral), sulfonylureas (high hypoglycemia risk), and thiazolidinediones (cause fluid retention, contraindicated in advanced heart failure).

Insulin Initiation: Indicated for severe hyperglycemia (glucose > 300 mg/dL or HbA1c > 10%) or symptomatic patients (weight loss, polyuria, polydipsia). Begin with basal insulin (10 units daily or 0.1–0.2 units/kg/day) and titrate based on fasting glucose.

Chronic Diabetic Complications and Metabolic Syndrome

Microvascular complications require strict screening and management:

Diabetic Kidney Disease: Screen annually with a urine albumin-to-creatinine ratio (UACR). If UACR is ≥ 30 mg/g, initiate an ACE inhibitor (e.g., lisinopril) or ARB (e.g., losartan), even in normotensive patients, to slow progression.

Diabetic Retinopathy: Screen with a dilated eye exam annually starting at diagnosis for type 2 diabetes (or 5 years after diagnosis for type 1).

Diabetic Neuropathy: Diabetic Neuropathy requires annual 10-g monofilament testing. Management of painful neuropathy includes pregabalin, duloxetine, or gabapentin. Gastroparesis presents with delayed gastric emptying; treat with small, low-fat meals and prokinetic agents like metoclopramide (limit use due to tardive dyskinesia risk) or erythromycin.

Macrovascular Risk: Patients aged 40–75 with diabetes require a moderate- to high-intensity statin for primary cardiovascular prevention, regardless of baseline LDL cholesterol.

Metabolic Syndrome: A cluster of risk factors predisposing to cardiovascular disease and type 2 diabetes. Diagnosis requires at least 3 of the following 5 criteria:

Waist Circumference: > 102 cm (40 inches) in men, or > 88 cm (35 inches) in women.

Triglycerides: ≥ 150 mg/dL (or on pharmacotherapy for hypertriglyceridemia).

HDL Cholesterol: < 40 mg/dL in men, or < 50 mg/dL in women (or on therapy).

Blood Pressure: Systolic ≥ 130 mmHg and/or diastolic ≥ 85 mmHg (or on antihypertensives).

Fasting Glucose: ≥ 100 mg/dL (or on glucose-lowering therapy).